First author | Sample size | Response rate % | Qual/Quanta | Method | MO | RO | Surg | Urologist | Others | Cancer streamb | Stage | Country | CPG focusc |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
O'Brien (2016) [54] | 28 | 68% | Qual | Interview | Y | Y | Y | - | – | Breast | Positive SLNB | Canada | cALND after positive sentinel lymph node biopsy (SLNB) regional CPG |
Shelton (2019) [55] | 42 | – | Qual | Interview | Y | – | Y | - | Y | Colon | Stage II | USA | Adjuvant chemotherapy for colon cancer national CPGs (ASCO or the NCCN) |
Otte (2017) [53] | 14 | – | Qual + Quant | Interview including Q card sorting | Y | – | – | - | – | Pancreatic ductal adeno-carcinoma | Locally advanced, UICC Stage III cT4N1M0 | Germany | Exocrine pancreatic adenocarcinoma Treatment CPGs, including recommendations for active cancer treatment and treatment with palliative intent |
Brouwers (2014) [56] | 71 | 30% | Qual + Quant | Surveys + interviews | Y | Y | Y | - | – | NSCLC | Stage II/IIIA resected NSCLC and unresected stage IIA/B NSCLC | Canada | 1. CCOPGI Chemotherapy CPG: stage II/IIIA resected NSCLC patients 2. CCOPGI Chemotherapy + radiation: unresected stage IIIA/B NSCLC patients |
Bristow (2018) [57] | 128 | - | Quant | Survey | – | Y | – | Y | Y | Prostate | Post-Prostatectomy | Canada | ASTRO and AUA Adjuvant and salvage post prostatectomy radiotherapy CPGs |
Brown (2016) [58] | 157 | 45% | Quant | Survey | – | – | – | Y | Y | Prostate | Locally advanced | Australia | ACN Adjuvant radiotherapy treatment for prostate cancer CPG |
Carrick (1998) [59] | 150 | 64% | Quant | Survey | – | – | Y | - | – | Breast | Early stage | Australia | NHMRC Early breast cancer management CPG |
Fonteyne (2018) [60] | 126 | 18% | Quant | Survey | Y | Y | – | Y | Y | MIBC | Primary to metastatic | Belgium | Primary, Adjuvant and metastatic radiotherapy treatment for MIBC |
Gattellari (2001) [61] | 195 | 89% | Quant | Survey | – | – | Y | - | – | CRC | – | Australia | ANC/COSA CRC management CPGs |
Graham (2007) [15] | 520 | 57% | Quant | Survey | Y | Y | – | - | Y | Cancer | – | Canada | CCOPGI cancer management CPGs |
Grilli (1991) [62] | 770 | 41% | Quant | Survey | Y | Y | – | - | Y | Breast, CRC, Ovarian | – | Italy | Italian National CPGs for Breast, CRC, and ovarian cancer treatment |
Ismaila (2018) [63] | 101 | 53% | Quant | Survey | – | Y | – | - | – | Cancer | – | Nigeria | International, national, local oncology CPGs |
Jagsi (2014) [64] | 896 | 60% | Quant | Survey | Y | – | Y | - | – | Breast | – | USA | NCCN CPG for Breast cancer |
Ward (1997) [65] | 69 | 77% | Quant | Survey | Y | Y | Y | - | Y | Breast | Early stage | Australia | NHMRC early breast cancer CPG |
White (2010) [66] | 63 (survey) | 58% | Quant | Survey + Patterns of care study | – | – | Y | - | – | Breast (DCIS) | DCIS | Australia | Australian treatment recommendations for DCIS |